ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)
China · Delayed Price · Currency is CNY 35.60
-0.88 (-2.41%)
Apr 9, 2026, 3:00 PM CST
ChengDu ShengNuo Biotec Revenue
In the year 2025, ChengDu ShengNuo Biotec had annual revenue of 741.34M CNY with 62.55% growth. ChengDu ShengNuo Biotec had revenue of 221.23M in the quarter ending December 31, 2025, with 87.11% growth.
Revenue
741.34M
Revenue Growth
+62.55%
P/S Ratio
7.56
Revenue / Employee
536.82K
Employees
1,450
Market Cap
5.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 741.34M | 285.27M | 62.55% |
| Dec 31, 2024 | 456.07M | 21.05M | 4.84% |
| Dec 31, 2023 | 435.02M | 39.30M | 9.93% |
| Dec 31, 2022 | 395.72M | 9.19M | 2.38% |
| Dec 31, 2021 | 386.53M | 7.76M | 2.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.63B |
| Jianmin Pharmaceutical Group | 3.37B |
| Jinling Pharmaceutical Company | 3.20B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Tianjin Lisheng Pharmaceutical | 1.39B |
| Beijing Beilu Pharmaceutical | 1.13B |
| Teyi Pharmaceutical Group Co.,Ltd | 924.53M |
| Nanjing Hicin Pharmaceutical | 615.39M |